Building a Road Map for Innovation: Strategic Clinical Technology Investment

Hong Kong Hospital Authority Convention 2008



Eric K Louie, MD, FACC Vice President, Sg2

5 May 2008



Medici Court 67-69 New Bond Street London W1S 1DF United Kingdom www.sg2.com

Agenda


Global Strategic Challenges in Health Care

Clinical Technologies Transforming Medicine Building Road Maps for Innovation





All Corners of the World Face Similar Strategic Challenges





Demographic Transformation Creates New Needs and Wants...

		2005 Demographic Indicators			2025 Demographic Indicators			
	2006 Population	Growth (%)	Life Expect at Birth (Y)	Infant Mort/ 1,000 Live Births	Growth (%)	Life Expect at Birth (Y)	Infant Mort/ 1,000 Live Births	
Philippines	90,780,000	/1.8	69.9	24	<u>, 1.2</u>	75.2	13	
Malaysia	26,900,000	1.8	72.2	18	1.4	76.9	10	
Cambodia	14,071,000	1.8	58.9	71	1.4	66.5	38	
India	1,124,400,000	1.7	67.2	40	1.2	77.8	10	
Singapore	4,483,900	1.6	81.6	2	0.2	83.1	2	
Indonesia	234,200,000	1.3	69.6	34	0.8	74.9	17	
Sri Lanka	20,905,000	1.2	74.5	20	0.5	78.2	11	
Vietnam	85,060,000	`1.0 ⁷	70.6	26	0.6	75.6	14	
US	301,300,000	0.9	77.7	6	0.8	80.5	5	
N Korea	23,250,000	0.9	71.4	24	0.4	76.3	13	
Australia	20,780,000	0.9	80.4	5	0.5	82.3	4	
Myanmar	50,519,000	0.8	61.6	54	0.4	68.9	29	
Thailand	64,990,000	0.7	72.0	20	0.2	76.6	11	
PRC	1,316,500,000	0.6	72.3	24	0.2	77.2	11	
Taiwan	23,155,000	0.6	77.3	6	0.1	80.3	5	
S Korea	49,024,737	0.4	76.8	6	0.0	80.1	5	
UK	60,541,000	0.3	78.4	5	0.2	80.1	4	

Sources: http://www.census.gov/ipc/www/popclockworld.html; Sg2 Analysis, 2008.



...Which Will Be Addressed by Strategic Investment in Clinical Technologies

	GDP/PPP (2006 Estimated Millions Standard International \$ Weights)	GDP/PPP per Capita	Real Growth Rate (%)	Health Care Expenditure per Capita (PPP\$)	Public Health Expenditure (% of GDP)	Total Health Care Expenditure (% of GDP)
Philippines	453,000	5,100	5.1		1.4	/Tx
Malaysia	290,200	21,100	5.3	152		(3.7)
Cambodia	30,650	2,200	6.0			
India	3,611,000	3,300	7.6	82/	1.2	2.6/
Singapore	124,300	28,100	6.4	1,156	1.6	4.2
Indonesia	856,600	3,600	5.6		1.1	
Sri Lanka	85,340	4,300	5.6		1.6	
Vietnam	232,200	2,800	8.4		1.5	
US	12,360,000	41,800	3.5	5,711	6.8	13.9
N Korea	40,000	1,700	1.0			
Australia	640,100	31,900	2.5	2,874	6.4	9.3
Myanmar	78,740	1,700	2.9	(51)	0.5	(3.3)
Thailand	560,700	8,300	4.5			3.3
PRC	8,859,000	6,800	9.9	278/		4.1/
Taiwan	631,200	27,600	3.8			6.2
S Korea	965,300	20,400	3.9			5.6
UK	1,830,000	30,300	1.8	2,389	6.9	7.9

Sources: The World Factbook, CIA, 2006; http://www.infoplease.com/ipa/A0874911.html; Human Development Report, 2006, United Nations; http://www.infoplease.com/ipa; Sg2 Analysis, 2008.

Acute Diseases Pose Global Health Threats, But Chronic Illnesses Are the Next Pandemic

For better or for worse, urbanisation and industrialisation are shaping the future threats to worldwide health.

Relative risk factors for cardiovascular disease in males >65 years old

Country	Mean Total Cholesterol (mmol/l*)	Hypertension Prevalence (>19/12 kPa [†])	Diabetes Prevalence	Smoking Prevalence	BMI >25 Prevalence				
US	5.1	41.4%	19.2%	8.6%	76.1%				
UK	5.7	66.6%	11.9%	17.0%	77.3%				
Germany	6.3	56.0%	12.7%	22.6%	81.0%				
France	5.9	80.5%	N/A	10.3%	N/A				
Japan	5.1	55.6%	29.4%	34.8%	30.1%				
China	5.4	58.9%	5.1%	42.0%	22.7%				
India	4.6	55.6%	28.5%	63.9%	24.8%				


*mmol/l x 39 = mg/dl cholesterol.

†140/90 mmHg = 19/12 kPa.

Sources: WHO Global InfoBase Online; World Bank Group; The World Factbook, CIA; Sg2 Analysis, 2007.

Will the Pacific Rim Migrate to the Sedentary Lifestyle and Rampant Obesity of the West?

Obesity impacts incidences of cardiovascular disease, musculoskeletal disease and some malignancies.



Sources: Jones S. Fashion world asks: How thin is too thin? Chicago Tribune 4 Feb 2007; Hossain P et al. N Engl J Med 2007;356:213-215; Sg2 Analysis, 2008.



... With Implications for the Global Burden of Diabetes, Vascular and Renal Diseases

ALL ALL	Patients With Diabetes, 2003 (Millions)	Increased Prevalence of Diabetes, 2000 to 2003		
Europe	37.4	32%		
North America	33.9	72%		
Australia	1.7	89%		
China	42.3	104%		
Latin America	33.0	148%		
India	79.4	150%		
South East Asia	58.1	161%		
Sub-Saharan Africa	18.6	162%		
Middle East	52.8	164%		

Sources: Jones S. Fashion world asks: How thin is too thin? Chicago Tribune 4 Feb 2007; Hossain P et al. N Engl J Med 2007;356:213–215; Sg2 Analysis, 2008.

Confidential and Proprietary © 2008 Sg2



Hospital Authority Convention 2007— Innovating for Health



Dr York Chow, Secretary for Health, Welfare and Food, Hong Kong Special Administrative Region, 7 May 2007

- Successful technologic innovation must:
 - Drive better health care outcomes and increased patient satisfaction
 - Result in broad application and scalability
 - Create affordable and sustainable opportunities

Value Creation Equitable and Accessible Care Sustainable Competitive Advantage

Sources: http://www.ha.org.hk/haconvention/hac2007proceedings/en_opening.html; Sg2 Analysis, 2008.



Agenda

Global Strategic Imperatives in Health Care


Clinical Technologies Transforming Medicine

Building Road Maps for Innovation






Clinical Innovation and Technological Change Enable Successful Care Transformation



Source: Sg2 Analysis, 2008.

Sg2's IoC Model Forecasts Future Resource Needs for Care Transformation





A Comprehensive Set of Factors Impact IP Utilisation, LOS and OP Visits

Sociocultural Factors

- Diabetes
- Obesity
- Respiratory pollutants
- Physical inactivity
- Smoking

Technology

- ICDs
- MIS hip and knee arthroplasty
- Carotid stenting with embolic protection
- Artificial discs


Outpatient Shift

- Uterine artery embolisation
- Image-guided focused ultrasound
- Unicompartmental knee replacement
- Noninvasive angiography
- Laparoscopic cancer surgery
- Hip resurfacing and MIS hip surgery
- Percutaneous radiofrequency ablation


Increased Hospitalisation

Care Delivery

- Defensive medicine
- Nonphysician/surgeon assistants
- Population-based screening for cancer and atherosclerosis




Health Care Is Comprised of a Matrix of Interlocking Programmes



Source: Sg2 Analysis, 2008.




Improved Management of CHF Requires Prevention and Preemption



*Ablative therapies and biventricular lead placement enabled by biplane imaging. Source: Sg2 Analysis, 2008.

Disease Management Redefines the Care Pyramid Across the Natural History of CHF




High-Volume Procedures

HF = heart failure; MI = myocardial infarction; LV = left ventricular; CAD = coronary artery disease.

Sources: *Olmsted County: Ammar KA et al. Circulation 2007;115:1563–1570; Yancy CW. Rev Cardiovasc Med 2005;6:S43–57; Sg2 Analysis, 2008.




... Refocusing on Interventions with Greatest Benefit at Lowest Cost Across the Care Cycle





Sources: Yancy Cw. Rev Cardiovasc Med 2005;6:S43-57; Sg2 Analysis, 2008.


Emerging Technologies Tailor Breast Cancer Care to Tumour Type and Patient Specifics





Breast Cancer: Comprehensive Programmatic Approach to the Care Continuum


Breast Cancer Care Path



Source: Sg2 Analysis, 2008.

Breast Screening and Diagnostics Triangulate Amongst Multiple Modalities

Elements of a Breast Cancer Screening Program





Personalised Medicine Targets Specific Tumour and Patient Attributes

Tumour-Specific Programs

Breast Tomosynthesis



Courtesy of Hologic

Molecular Medicine

Microarray



Targeting the Tumour (Her-2 Amplification by FISH, Onco*type* DX[®])


- Increased tumour subspecialisation
- Improved prediction of prognosis and response to therapy
- More targeted treatments requiring linked diagnostics

Treating the Patient

- Organ is imaged and biopsied for disease.
- Patient endures organ-specific surgery and radiation.
- Patient suffers and needs supportive services.




MIS Techniques Enable LOS Reduction in Joint Replacement






... But Care Optimisation Necessitates Expanding the Frame of Reference...





... To Include the Entire Cycle of Care






Agenda

Global Strategic Imperatives in Health Care Clinical Technologies Transforming Medicine Building Road Maps for Innovation





Strategic Technology Investment Requires Programmatic Development





Profile: An Example— Assessing an Oncology Programme



	1	2	3	4	5	Considerations
Imaging						 Leader in screening lung CT Still undecided on digital mammography offerings Plans in place but currently behind in general CT and MRI offerings
Surgery						 Well-established laparoscopic practice and leadership Historic leader in robotic technology
Radiation Oncology						 Essentially complete array of treatment options
Medical Oncology						Minimal drug trial participationNo genetic testing
Path/Lab/IT						 Hospital-wide PACS Significant updates to RIS necessary Planning on EMR and CPOE



Profile: Taking An External Point of View






NASA Johnson Space Center - Earth Sciences and Image Analysis (NASA-JSC-ES&IA).


Market Assessment



Staffing and Manpower Analysis



Demand Forecasting



Competitor Evaluation



Confidential and Proprietary © 2008 Sg2

Plan: Defining the Value Proposition




Destination (Technical Expertise Characterised by significant capit investments in technology and cli expertise that pulls tertiary and quaternary referrals	(Custom Characterised by a	sed Care Intimacy) ocus on coordinated and pleasing	Value Offering (Efficiency, High Throughput) Characterised by a focus on efficient patient work flow processes, access and convenience		
 customer acquisition. Differentiates system and brand as cutting edge health care provider Halo effect can lead to secondary referrals. High entry barriers due to significant capital requirements capital exp Competitor imitate by a similar cap Threat of displacement later cheap distributed technology Success con upon succes 	nditurescustomer retention.can• Difficult forquiring• Difficult forpolities.• Decause successfulbilities.• Difficult forcoordination of care• Difficult fort by• Decause successfulr,• Difficult forr,• Difficult for <th>Significant initial capital expenditures Competitors can imitate by acquiring similar capabilities. Threat of displacement by later cheaper,</th> <th> Significant initial investment in information technology Success is contingent on the quality and soft skills of front line clinicians and support staff, which will require higher levels of local management. </th> <th> Pros Emphasis is on both customer acquisition and retention. Imitation by competition requires an investment in enabling technologies and process engineering. Expected growth in robotics and MIS techniques supports high-throughput value proposition. </th> <th>Cons • Vulnerable to replication due to low barriers to entry</th>	Significant initial capital expenditures Competitors can imitate by acquiring similar capabilities. Threat of displacement by later cheaper,	 Significant initial investment in information technology Success is contingent on the quality and soft skills of front line clinicians and support staff, which will require higher levels of local management. 	 Pros Emphasis is on both customer acquisition and retention. Imitation by competition requires an investment in enabling technologies and process engineering. Expected growth in robotics and MIS techniques supports high-throughput value proposition. 	Cons • Vulnerable to replication due to low barriers to entry



Plan: An Example— Setting Priorities in Oncology








Manage: An Example— Building the Road Map for Oncology






Note: Timings reflect consensus adoption. Source: Sg2 Analysis, 2008.



Manage: Programmatic Development & Performance






The Future of Health Care Hinges on Creating Value in a Competitive Market

Redefining Health Care *Creating Value-Based Competition on Results*

Changing the game from zero sum to positive sum competition Michael Porter and Elizabeth Olmsted Teisberg





Superior Performance Will Require the Transformation from Independence into Interdependence

Yesterday

- Clinician-focused
- Privileged access of information
- Deferral to clinician authority
- Subspecialty silos
- Artisan culture of craftsmanship and one-off solutions
- Autonomy requiring individual responsibility for error avoidance

Tomorrow

- Patient-centred
- Information transparency
- Empowerment of patient choice
- Cross-functional teams
- Evidence-based standards and care pathways
- Interdependence requiring system solutions for error preemption

Sources: IOM. To Err Is Human: Building a Safer Health System 2000; IOM. Crossing the Quality Chasm 2001; Sg2 Analysis, 2007.



health care intelligence

Sg2 is a forward-thinking health care research, consulting and education company. Sg2 analyses emerging clinical developments, technological advancements and market trends to help clients make informed business decisions, advance clinical excellence, streamline operations, grow market share and exceed financial goals.